SE0104333D0 - Therapeutic agents - Google Patents

Therapeutic agents

Info

Publication number
SE0104333D0
SE0104333D0 SE0104333A SE0104333A SE0104333D0 SE 0104333 D0 SE0104333 D0 SE 0104333D0 SE 0104333 A SE0104333 A SE 0104333A SE 0104333 A SE0104333 A SE 0104333A SE 0104333 D0 SE0104333 D0 SE 0104333D0
Authority
SE
Sweden
Prior art keywords
sup
well
therapeutic agents
racemates
prodrugs
Prior art date
Application number
SE0104333A
Other languages
English (en)
Inventor
Alstermark Eva-Lotte Lindstedt
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Priority to SE0104333A priority Critical patent/SE0104333D0/sv
Publication of SE0104333D0 publication Critical patent/SE0104333D0/sv
Priority to PL02370623A priority patent/PL370623A1/xx
Priority to UA20040604534A priority patent/UA80407C2/uk
Priority to US10/499,042 priority patent/US7276539B2/en
Priority to NZ533365A priority patent/NZ533365A/en
Priority to EP02788144A priority patent/EP1458677B1/en
Priority to TW091136517A priority patent/TW200410678A/zh
Priority to AT02788144T priority patent/ATE428691T1/de
Priority to PCT/GB2002/005743 priority patent/WO2003051826A1/en
Priority to DE60232018T priority patent/DE60232018D1/de
Priority to MXPA04005992A priority patent/MXPA04005992A/es
Priority to CA002470066A priority patent/CA2470066C/en
Priority to IL16237802A priority patent/IL162378A0/xx
Priority to AU2002352426A priority patent/AU2002352426A1/en
Priority to CNB028281225A priority patent/CN100343229C/zh
Priority to RU2004117776/04A priority patent/RU2004117776A/ru
Priority to JP2003552714A priority patent/JP3810770B2/ja
Priority to KR10-2004-7009348A priority patent/KR20040068589A/ko
Priority to BR0215090-5A priority patent/BR0215090A/pt
Priority to ES02788144T priority patent/ES2324025T3/es
Priority to HU0402093A priority patent/HUP0402093A3/hu
Priority to ARP020105003A priority patent/AR038046A1/es
Priority to IS7303A priority patent/IS7303A/is
Priority to ZA200404585A priority patent/ZA200404585B/en
Priority to CO04068143A priority patent/CO5590908A2/es
Priority to NO20043084A priority patent/NO20043084L/no
Priority to HK05100665.9A priority patent/HK1068866A1/xx
Priority to JP2006077296A priority patent/JP2006241162A/ja

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/50Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton
    • C07C323/51Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C323/56Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton containing six-membered aromatic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/192Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives
SE0104333A 2001-12-19 2001-12-19 Therapeutic agents SE0104333D0 (sv)

Priority Applications (28)

Application Number Priority Date Filing Date Title
SE0104333A SE0104333D0 (sv) 2001-12-19 2001-12-19 Therapeutic agents
HU0402093A HUP0402093A3 (en) 2001-12-19 2002-12-18 3-phenyl-2-phenethylthio-propionic acid derivatives as selective agonists of ppar-alpha, their preparation and pharmaceutical compositions containing them
IL16237802A IL162378A0 (en) 2001-12-19 2002-12-18 3-Phenyl-2-arylalkylthiopropionic acid derivativesas selective agonists of ppar-al-pha
CNB028281225A CN100343229C (zh) 2001-12-19 2002-12-18 作为选择性PPAR-α激动剂的3-苯基-2-芳基烷基硫代丙酸衍生物
US10/499,042 US7276539B2 (en) 2001-12-19 2002-12-18 3-Phenyl-2-arylalkylthiopropionic acid derivatives as selective agonists of ppar-alpha
NZ533365A NZ533365A (en) 2001-12-19 2002-12-18 3-Phenyl-2-arylalkylthiopropionic acid derivatives as selective agonists of ppar-alpha
EP02788144A EP1458677B1 (en) 2001-12-19 2002-12-18 3-phenyl-2-arylalkylthiopropionic acid derivatives as selective agonists of ppar-alpha
TW091136517A TW200410678A (en) 2001-12-19 2002-12-18 Therapeutic agents
AT02788144T ATE428691T1 (de) 2001-12-19 2002-12-18 3-phenyl-2-arylalkylthiopropionsäure-derivate als selektive agonisten von ppar-alpha
PCT/GB2002/005743 WO2003051826A1 (en) 2001-12-19 2002-12-18 3-phenyl-2-arylalkylthiopropionic acid derivatives as selective agonists of ppar-alpha
DE60232018T DE60232018D1 (de) 2001-12-19 2002-12-18 3-phenyl-2-arylalkylthiopropionsäure-derivate als selektive agonisten von ppar-alpha
MXPA04005992A MXPA04005992A (es) 2001-12-19 2002-12-18 Derivados de acido 3-fenil-2-arilalquiltiopropionico como antagonistas selectivos de ppar-alfa.
CA002470066A CA2470066C (en) 2001-12-19 2002-12-18 3-phenyl-2-arylalkylthiopropionic acid derivatives as selective agonists of ppar-alpha
PL02370623A PL370623A1 (en) 2001-12-19 2002-12-18 3-phenyl-2-arylalkylthiopropionic acid derivatives as selective agonists of ppar-alpha
AU2002352426A AU2002352426A1 (en) 2001-12-19 2002-12-18 3-phenyl-2-arylalkylthiopropionic acid derivatives as selective agonists of ppar-alpha
UA20040604534A UA80407C2 (en) 2001-12-19 2002-12-18 3-phenyl-2-arylalkylthiopropionic acid derivatives as selective agonists of parp-alpha
RU2004117776/04A RU2004117776A (ru) 2001-12-19 2002-12-18 Производные 3-фенил-2-арилалкилтиопропионовой кислоты в качестве селективных антагонистов ppar-альфа
JP2003552714A JP3810770B2 (ja) 2001-12-19 2002-12-18 PPARαの選択的アンタゴニストとしての3−フェニル−2−アリールアルキルチオプロピオン酸誘導体
KR10-2004-7009348A KR20040068589A (ko) 2001-12-19 2002-12-18 Ppar-알파의 선택적 효능제로서3-페닐-2-아릴알킬티오프로피온산 유도체
BR0215090-5A BR0215090A (pt) 2001-12-19 2002-12-18 Composto, enanciÈmero (r) ou enanciÈmero (s) de um composto, formulação farmacêutica, método para tratar ou prevenir distúrbios lipìdicos (dislipidemia) associados ou não com resistência à insulina, uso de um composto, método para tratar ou prevenir diabetes de tipo 2, processo para preparar um composto, e, composição farmacêutica
ES02788144T ES2324025T3 (es) 2001-12-19 2002-12-18 Derivados del acido 3-fenil-2-arilalquiltiopropionico como agonistas selectivos de ppar-alfa.
ARP020105003A AR038046A1 (es) 2001-12-19 2002-12-19 Derivados de acidos 3-fenil-2-arilalquiltiopropionicos moduladores de ppar alfa
IS7303A IS7303A (is) 2001-12-19 2004-06-08 3-fenýl-2-arýlalkýlþíóprópíónsýruafleiður sem valvís gerandefni PPAR-ALFA
ZA200404585A ZA200404585B (en) 2001-12-19 2004-06-09 3-Phenyl-2-arylalkylthiopropionic acid derivativesas selective agonists of PPAR-alpha.
CO04068143A CO5590908A2 (es) 2001-12-19 2004-07-16 Derivados de acido 3-fenil-2-arilalquiltiopropionico como antagonistas selectivos de ppar-alfa
NO20043084A NO20043084L (no) 2001-12-19 2004-07-16 3-fenyl-2-arylalkyltiopropionsyre derivater som selektive agnoister av PPAR-ALPHA
HK05100665.9A HK1068866A1 (en) 2001-12-19 2005-01-25 3-phenyl-2-arylalkylthiopropionic acid derivatives as selective agonists of ppar-alpha
JP2006077296A JP2006241162A (ja) 2001-12-19 2006-03-20 PPARαの選択的アンタゴニストとしての3−フェニル−2−アリールアルキルチオプロピオン酸誘導体

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE0104333A SE0104333D0 (sv) 2001-12-19 2001-12-19 Therapeutic agents

Publications (1)

Publication Number Publication Date
SE0104333D0 true SE0104333D0 (sv) 2001-12-19

Family

ID=20286432

Family Applications (1)

Application Number Title Priority Date Filing Date
SE0104333A SE0104333D0 (sv) 2001-12-19 2001-12-19 Therapeutic agents

Country Status (27)

Country Link
US (1) US7276539B2 (sv)
EP (1) EP1458677B1 (sv)
JP (2) JP3810770B2 (sv)
KR (1) KR20040068589A (sv)
CN (1) CN100343229C (sv)
AR (1) AR038046A1 (sv)
AT (1) ATE428691T1 (sv)
AU (1) AU2002352426A1 (sv)
BR (1) BR0215090A (sv)
CA (1) CA2470066C (sv)
CO (1) CO5590908A2 (sv)
DE (1) DE60232018D1 (sv)
ES (1) ES2324025T3 (sv)
HK (1) HK1068866A1 (sv)
HU (1) HUP0402093A3 (sv)
IL (1) IL162378A0 (sv)
IS (1) IS7303A (sv)
MX (1) MXPA04005992A (sv)
NO (1) NO20043084L (sv)
NZ (1) NZ533365A (sv)
PL (1) PL370623A1 (sv)
RU (1) RU2004117776A (sv)
SE (1) SE0104333D0 (sv)
TW (1) TW200410678A (sv)
UA (1) UA80407C2 (sv)
WO (1) WO2003051826A1 (sv)
ZA (1) ZA200404585B (sv)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR0311932A (pt) 2002-06-20 2005-03-22 Astrazeneca Ab Composto, formulação farmacêutica, método para tratar ou prevenir resistência à insulina, uso de um composto, processo para preparar um composto, e, tratamento combinado
GB0314130D0 (en) * 2003-06-18 2003-07-23 Astrazeneca Ab Therapeutic agents
GB0314131D0 (en) * 2003-06-18 2003-07-23 Astrazeneca Ab Therapeutic agents
GB0314075D0 (en) * 2003-06-18 2003-07-23 Astrazeneca Ab Therapeutic agents
GB0314134D0 (en) * 2003-06-18 2003-07-23 Astrazeneca Ab Therapeutic agents
GB0314260D0 (en) 2003-06-19 2003-07-23 Astrazeneca Ab Therapeutic agents
GB0427524D0 (en) * 2004-12-16 2005-01-19 Astrazeneca Ab Chemical process
GB0427701D0 (en) * 2004-12-17 2005-01-19 Astrazeneca Ab Therapeutic agents
ES2445049T3 (es) 2007-03-08 2014-02-27 Albireo Ab Derivados del ácido 3-fenilpropiónico y su uso en el tratamiento de la enfermedad inflamatoria intestinal

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5089514A (en) 1990-06-14 1992-02-18 Pfizer Inc. 3-coxazolyl [phenyl, chromanyl or benzofuranyl]-2-hydroxypropionic acid derivatives and analogs as hypoglycemic agents
US5232945A (en) * 1992-07-20 1993-08-03 Pfizer Inc. 3-aryl-2-hydroxypropionic acid derivatives and analogs as antihypertensives
AU1903799A (en) 1997-12-05 1999-06-28 Eisai Co. Ltd. Compositions and methods for modulating the activity of fibroblast growth factor
EP1067109B1 (en) * 1998-03-10 2009-12-09 Ono Pharmaceutical Co., Ltd. Carboxylic acid derivatives and drugs containing the same as the active ingredient
MA26634A1 (fr) * 1998-06-04 2004-12-20 Astra Ab Nouveaux derives de l'acide 3-aryl propionique et analogues
SE9801992D0 (sv) * 1998-06-04 1998-06-04 Astra Ab New 3-aryl-2-hydroxypropionic acid derivative I
SE9801990D0 (sv) 1998-06-04 1998-06-04 Astra Ab New 3-aryl propionic acid derivatives and analogs
GB9822473D0 (en) * 1998-10-16 1998-12-09 Glaxo Group Ltd Chemical compounds
EE200100556A (et) 1999-04-28 2003-02-17 Aventis Pharma Deutschland Gmbh Diarüülhappe derivaat, seda sisaldav farmatseutiline kompositsioon ja ühendi kasutamine ravimite valmistamiseks
TWI262185B (en) 1999-10-01 2006-09-21 Eisai Co Ltd Carboxylic acid derivatives having anti-hyperglycemia and anti-hyperlipemia action, and pharmaceutical composition containing the derivatives
TW574193B (en) 1999-12-03 2004-02-01 Astrazeneca Ab Novel phenalkyloxy-phenyl derivatives, pharmaceutical composition containing the same and their uses
SE9904421D0 (sv) 1999-12-03 1999-12-03 Astra Ab New compounds
SE0000772D0 (sv) * 2000-03-08 2000-03-08 Astrazeneca Ab Chemical compounds
KR20020081424A (ko) 2000-03-09 2002-10-26 아벤티스 파마 도이칠란트 게엠베하 Ppar 매개인자의 치료학적 용도
SE0003766D0 (sv) 2000-10-18 2000-10-18 Astrazeneca Ab Novel formulation
EG26979A (en) 2000-12-21 2015-03-01 Astrazeneca Ab Chemical compounds
TWI311133B (en) * 2001-04-20 2009-06-21 Eisai R&D Man Co Ltd Carboxylic acid derivativeand the salt thereof
SE0101978D0 (sv) 2001-06-01 2001-06-01 Astrazeneca Ab New compounds
GB0121337D0 (en) 2001-09-04 2001-10-24 Astrazeneca Ab Chemical compounds
GB0121621D0 (en) 2001-09-07 2001-10-31 Astrazeneca Ab Chemical compounds
GB0121622D0 (en) 2001-09-07 2001-10-31 Astrazeneca Ab Chemical compounds
IL160691A0 (en) 2001-09-08 2004-08-31 Astrazeneca Ab Benzothiazepine and benzothiadiazepine derivatives with ileal bile acid transport (ibat) inhibitory activity for the treatment of hyperlipidaemia
SE0104334D0 (sv) 2001-12-19 2001-12-19 Astrazeneca Ab Therapeutic agents
GB0229931D0 (en) 2002-12-21 2003-01-29 Astrazeneca Ab Therapeutic agents
GB0209467D0 (en) 2002-04-25 2002-06-05 Astrazeneca Ab Chemical compounds
GB0213669D0 (en) 2002-06-14 2002-07-24 Astrazeneca Ab Chemical compounds
SE0201937D0 (sv) 2002-06-20 2002-06-20 Astrazeneca Ab Therapeutic agents
BR0311932A (pt) 2002-06-20 2005-03-22 Astrazeneca Ab Composto, formulação farmacêutica, método para tratar ou prevenir resistência à insulina, uso de um composto, processo para preparar um composto, e, tratamento combinado
SE0201936D0 (sv) 2002-06-20 2002-06-20 Astrazeneca Ab Therapeutic agents
GB0314075D0 (en) 2003-06-18 2003-07-23 Astrazeneca Ab Therapeutic agents
GB0314136D0 (en) 2003-06-18 2003-07-23 Astrazeneca Ab Therapeutic agents
GB0314129D0 (en) 2003-06-18 2003-07-23 Astrazeneca Ab Therapeutic agents
GB0314078D0 (en) 2003-06-18 2003-07-23 Astrazeneca Ab Therapeutic agents
GB0314130D0 (en) * 2003-06-18 2003-07-23 Astrazeneca Ab Therapeutic agents
GB0314131D0 (en) 2003-06-18 2003-07-23 Astrazeneca Ab Therapeutic agents
GB0314260D0 (en) 2003-06-19 2003-07-23 Astrazeneca Ab Therapeutic agents

Also Published As

Publication number Publication date
ATE428691T1 (de) 2009-05-15
CA2470066A1 (en) 2003-06-26
RU2004117776A (ru) 2006-01-10
KR20040068589A (ko) 2004-07-31
HUP0402093A3 (en) 2008-08-28
NO20043084L (no) 2004-07-16
CA2470066C (en) 2007-04-10
EP1458677B1 (en) 2009-04-15
JP3810770B2 (ja) 2006-08-16
US20050215630A1 (en) 2005-09-29
PL370623A1 (en) 2005-05-30
ZA200404585B (en) 2005-10-26
US7276539B2 (en) 2007-10-02
JP2005511785A (ja) 2005-04-28
DE60232018D1 (de) 2009-05-28
CN100343229C (zh) 2007-10-17
AU2002352426A1 (en) 2003-06-30
ES2324025T3 (es) 2009-07-29
TW200410678A (en) 2004-07-01
AR038046A1 (es) 2004-12-22
MXPA04005992A (es) 2004-09-27
CO5590908A2 (es) 2005-12-30
WO2003051826A1 (en) 2003-06-26
UA80407C2 (en) 2007-09-25
HUP0402093A2 (hu) 2005-02-28
IS7303A (is) 2004-06-08
IL162378A0 (en) 2005-11-20
EP1458677A1 (en) 2004-09-22
JP2006241162A (ja) 2006-09-14
BR0215090A (pt) 2004-11-16
HK1068866A1 (en) 2005-05-06
NZ533365A (en) 2006-05-26
CN1620430A (zh) 2005-05-25

Similar Documents

Publication Publication Date Title
SE0104334D0 (sv) Therapeutic agents
TW200508180A (en) Therapeutic agents
SE0302487D0 (sv) Novel compounds
CO5271691A1 (es) Nuevos compuestos
HK1089163A1 (en) Quinoxaline derivatives as neutrophil elastase inhibitors and their use
DE60315674D1 (de) Neue imidazopyridine und ihre verwendung
SE9904176D0 (sv) New use
MY137156A (en) Dual nk1/nk3 derivatives
SE0202463D0 (sv) Novel compounds
SE0302323D0 (sv) Novel compounds
UA66852C2 (uk) Похідні та аналоги 3-арилпропіонової кислоти, спосіб їх отримання, фармацевтична композиція (варіанти) та спосіб профілактики та/або лікування асоційованих з резистентністю до інсуліну клінічних станів
BR0313407A (pt) Novo uso de derivados de benzotiazol
SE9903997D0 (sv) New compounds
SE0104333D0 (sv) Therapeutic agents
SE0302756D0 (sv) Novel Compounds
IL166103A0 (en) Pyrrolidine derivatives and their use
SE0102057D0 (sv) New Salts I
SE0102058D0 (sv) New Salts II
DK0556813T3 (da) Amfotere tricykliske forbindelser som antihistaminske og antiallergiske midler
DE60103034D1 (de) Neue phenylheteroalkylamin-derivate
SE0201936D0 (sv) Therapeutic agents
SE0102640D0 (sv) Novel compounds
TW200502202A (en) Therapeutic agents
SE9901530D0 (sv) Novel compounds
SE0201935D0 (sv) Therapeutic agents